Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
Displaying: 713 trials in your specialties ()
View trials across your selected specialties

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Advanced Pancreatic Cancer
View Full Trial
INTERVENTION

Biological: Cabiralizumab, Drug: Nab-paclitaxel, Drug: Onivyde, Biological: Nivolumab, Drug: Fluorouracil, Drug: Gemcitabine, Drug: Oxaliplatin, Drug: Leucovorin, Drug: Irinotecan Hydrochloride

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic - PPDS, Phoenix, Arizona, United States

Brief Summary

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Pancreatic Adenocarcinoma
View Full Trial
INTERVENTION

Drug: Gemcitabine, Drug: Nab-paclitaxel, Drug: Durvalumab, Drug: Tremelimumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Brief Summary

The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Untreated Metastatic Pancreatic Ductal Adenocarcinoma
View Full Trial
INTERVENTION

Drug: Nivolumab, Drug: Albumin-bound paclitaxel, Drug: Paricalcitol, Drug: Cisplatin, Drug: Gemcitabine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

HonorHealth Research Institute, Scottsdale, Arizona, United States

Brief Summary

The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to treat advanced pancreatic cancer.

A Study of Anti-PD-L1 Antibody in Perioperative Chemotherapy of Esophageal Carcinoma.

  • Status
    Not yet recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Esophageal Cancer
View Full Trial
INTERVENTION

Drug: anti-PD-L1 antibody, Drug: albumin bound paclitaxel, Drug: cisplatin, Drug: placebo, Procedure: radical resection of esophageal carcinoma

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Brief Summary

This is a randomized, double-blind, placebo-controlled Ib/Ⅱ clinical study to evaluate the safety and effect of anti-PD-L1 antibody (ZKAB001) in perioperative chemotherapy of esophageal squamous carcinoma in combination with Alb-paclitaxel and cisplatin. The immunotherapy will be given before and after the operation every three weeks.

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Lung Cancer, Non-small Cell
View Full Trial
INTERVENTION

Drug: Camrelizumab + Nab-paclitaxel + Carboplatin

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Brief Summary

This is an open-label, single-arm, phase II, multi-centre clinical trial. Patients will receive Camrelizumab 200mg + Nab-paclitaxel 260mg/m2 + Carboplatin AUC5 for 3 cycles every 21 days (+/- 3 days) as neoadjuvant treatment followed by surgery. All participants who undergo surgery will enter a surveillance period, which consists of standardized blood sample collection and Chest CT Scans, for up to 2 years. All participants will be monitored for disease recurrence and survival for up to 3 years after last dose of study drug.The study aims to determine if chemotherapy combined with immune-based therapy can lead to improvement in Major pathologic response (MPR) Rate over historical MPR with chemotherapy alone.

PD-1 Inhibitors and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma o...
View Full Trial
INTERVENTION

Radiation: Radiotherapy, Drug: Pembrolizumab, Drug: Chemotherapy

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Institut Sainte Catherine, Avignon, France

Brief Summary

Overall survival (OS) of patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC) remains short after the first line of treatment with a median OS of 12.2 months in non squamous NSCLC and 9.2 months in squamous NSCLC . In this setting the programmed death 1/ligand 1 (PD-1/-L1) were targeted with nivolumab (IgG4) in advanced squamous and nonsquamous NSCLC leading to an increase of the 1-year OS rate of approximately 10-15% in both histologies. Nivolumab, pembrolizumab and atezolizumab are now considered a standard of care in 2nd line advanced NSCLC and in 1st line for pembrolizumab but but prognosis still remains poor in advanced NSCLC. Overall survival (OS) of patients with advanced (stage III/IV) NSCLC remains limited with a median OS of 12.2 months in non-squamous NSCLC and 9.2 months in squamous NSCLC if anti-PD1 alone. It is of around 16 months if pembrolizumab is combined with chemotherapy. Preclinical data indicates that anti-tumor efficacy is increased when anti-PD-1/-L1 are combined with irradiation (IR). Radiotherapy alone can elicit tumor cell death which can increase tumor antigen in the blood stream, favoring recognition by the immune system and its activation against tumor cells outside of the radiation field (="abscopal effect"). IR may also reverse acquired resistance to PD-1 blockade immunotherapy by limiting T-cell exhaustion. Because of these preclinical and clinical data several studies analysing the combination of IR and anti-PD1 in NSCLC are ongoing. Among them, two studies are testing the administration of IR and nivolumab in stage III NSCLC: the NCT02768558 phase III trial (RTOG), and the NCT02434081 phase II trial (ETOP). Antonia et al [2017] tested the use of anti-PD-L1 after chemoradiotherapy in unresectable stage III NSCLC. Median time to distant metastasis was increased (23.2 months vs. 14.6 months, p<0.001). An increase of OS is consequently expected. However, no study involving concurrent RT and pembrolizumab combined with chemotherapy in advanced NSCLC is ongoing, which is the purpose of the present study, NIRVANA-Lung.

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Tri...
View Full Trial
INTERVENTION

Biological: CAN04, Drug: Cisplatin, Drug: Gemcitabine, Drug: Nab-paclitaxel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Hospital 12 de Octubre, Madrid, Spain

Brief Summary

This study will evaluate the safety, tolerability, and preliminary antitumor activity of CAN04 both as a monotherapy and in combination with standard of care treatment in subjects with solid cancer tumors. Following completion of the first part, the dose escalation cohorts, and determination of maximum tolerated dose or recommended phase 2 dose (MTD/RP2D), safety and tolerability will be further evaluated in an expanded cohort of subjects with pancreatic or lung cancer, as monotherapy or in combination with the standard of care treatment. In addition, early signs of efficacy during treatment with CAN04 will be investigated.

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Small Cell Lung Cancer (SCLC)
View Full Trial
INTERVENTION

Drug: Nab-paclitaxel, Drug: Gemcitabine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Brief Summary

The purpose of this research study is to see if Abraxane and Gemcitabine given together will be effective in treating small cell cancer that has progressed after one line of treatment.

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Gastroesophageal Cancer
View Full Trial
INTERVENTION

Drug: nab-paclitaxel, Biological: ramucirumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Rocky Mountain Cancer Centers, Denver, Colorado, United States

Brief Summary

The purpose of this study is to determine whether nab-Paclitaxel (Abraxane®) and ramucirumab (Cyramza®) are effective when used in combination for treating patients with metastatic gastroesophageal cancer who have either progressed or not responded to prior therapy.

Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Cancer
View Full Trial
INTERVENTION

Drug: Gemcitabine, Drug: Nab-paclitaxel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States

Brief Summary

This is a research study for people who have a solid tumor that was not effectively treated by conventional therapy or for which there is no known effective therapy. This is a phase I study of a drug called nab-paclitaxel used together with gemcitabine. Gemcitabine and nab-paclitaxel will be given intravenously, once a week for 3 out of 4 weeks, for a 28-day cycle. The goals of this study are: - To find the highest dose of nab-paclitaxel that can be safely given in combination with gemcitabine without causing severe side effects - To learn what kind of side effects nab-paclitaxel given in combination with gemcitabine can cause - To learn more about the pharmacology (how the body handles the drug) of nab-paclitaxel given in combination with gemcitabine - To evaluate tumor tissue for levels of certain proteins that may help with predicting who will benefit most from treatment with nab-paclitaxel - To determine whether nab-paclitaxel given in combination with gemcitabine is a beneficial treatment for relapsed and/or refractory solid tumors